https://doi.org/10.4081/reumatismo.2018.1062

Update on treatment of polymyalgia rheumatica

Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
Submitted: 17 August 2017
Accepted: 8 February 2018
Published: 27 March 2018
Polymyalgia rheumatica, large vessel vasculitis, glucocorticoids, disease modifying anti-rheumatic drugs, biologics.
Abstract Views: 5449
PDF: 3247
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

D. Camellino
dario.camel@gmail.com
http://orcid.org/0000-0001-6384-6458
Division of Rheumatology, Locomotor Apparatus Department, La Colletta Hospital, ASL3 Genovese, Arenzano (GE); Autoimmunology Lab, Department of Internal Medicine, University of Genova, Italy.
C. Dejaco
Service of Rheumatology, ASL dell’Alto Adige, Hospital of Brunico, Brunico (BZ), Italy; Department of Rheumatology, University of Medicine of Graz, Graz, Austria.
Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
D. Camellino, Division of Rheumatology, Locomotor Apparatus Department, La Colletta Hospital, ASL3 Genovese, Arenzano (GE); Autoimmunology Lab, Department of Internal Medicine, University of Genova
Specializzando in Reumatologia

How to Cite

Camellino, D., & Dejaco, C. (2018). Update on treatment of polymyalgia rheumatica. Reumatismo, 70(1), 59–66. https://doi.org/10.4081/reumatismo.2018.1062

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 47 48 49 50 51 52 53 54 55 56 > >> 

You may also start an advanced similarity search for this article.